Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 7708 results

  1. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977

    Awaiting development [GID-TA11507] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development [GID-TA11509] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Virtual Wards for Heart Failure

    Awaiting development [GID-MT609] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  4. Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

    Awaiting development [GID-TA11254] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Awaiting development [GID-TA10897] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development [GID-TA11368] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  9. Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

    In development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  11. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  12. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. RespiraSense (MT736)

      Status ...

    Medical technologies guidance
    Topic selection

  15. CytoSorb for reducing risk of bleeding during cardiac surgery

      Status ...

    Medical technologies guidance
    Topic selection